An overview of eight randomized controlled trials of tissue-type plasminogen activator (Alteplase or Duteplase) and 10 of anisoylated plasminogen streptokinase activator complex (Anistreplase) showed that the odds of early death were reduced by 29%o by tissue-type plasminogen activator and 46% by anisoylated plasminogen streptokinase activator complex, with overlapping 95% confidence intervals. Although the beneficial effects of both agents are consistent and are strengthened when all the trials are considered together, the available data do not permit comparisons of the relative efficacy of these two agents with each other or with streptokinase. (Circulation 1990;82:1668-1674 T he use of intravenous thrombolytic therapy in acute myocardial infarction (MI) Both t-PA and APSAC have been evaluated in moderately large controlled trials. In addition to one such trial with each agent,78 data are available from several small trials in which improvement in left ventricular function or coronary artery recanalization or patency were the main outcomes of interest. The number of patients entered into the aggregate of these small trials and the number of deaths reported are substantial enough to double the information on mortality on APSAC and to increase considerably that on t-PA. The aims of this study are, first, to examine the extent to which an overview of the small trials of each agent confirms the benefit reported in the large trials, and second, to conduct a systematic overview of the mortality results in all randomized controlled trials of each agent to provide the best possible estimate of the effects of t-PA and APSAC on mortality.
but not all studies,5 these newer agents appear to produce higher rates of coronary artery recanalization or patency when arteriograms were obtained at 60-90 minutes after the start of intravenous therapy. Additionally, these agents, particularly t-PA, are believed to have a more selective effect on fibrin deposited in clots.4.6 These theoretical considerations have raised the possibility that the newer agents might reduce mortality to a larger degree than achieved by streptokinase.
Both t-PA and APSAC have been evaluated in moderately large controlled trials. In addition to one such trial with each agent,78 data are available from several small trials in which improvement in left ventricular function or coronary artery recanalization or patency were the main outcomes of interest. The number of patients entered into the aggregate of these small trials and the number of deaths reported are substantial enough to double the information on mortality on APSAC and to increase considerably that on t-PA. The aims of this study are, first, to examine the extent to which an overview of the small trials of each agent confirms the benefit reported in the large trials, and second, to conduct a systematic overview of the mortality results in all randomized controlled trials of each agent to provide the best possible estimate of the effects of t-PA and APSAC on mortality.
Methods
The intent was to obtain data on mortality from each completed, published or unpublished, randomized controlled trial of t-PA and APSAC in acute MI. Our method was to scan the literature by formal and informal searches for studies that were known to ourselves or our coworkers, to scan the reference lists of the published papers, and to inquire of our colleagues about unpublished trials. The statistical methods used are similar to those described and used previously.9 Outcome data from the different trials were combined by the Mantel-Haenszel method. The analyses have been performed separately for each agent.
The underlying principle is that patients allocated to active treatment in one trial are compared directly only with those allocated to control in the same trial and not with patients in any other trial. Therefore, differences in patient characteristics between trials do not matter, as long as the patients are broadly similar (e.g., suspected acute MI). For example, there may be wide variability in control group mortality among the trials because of differences in the types of patients enrolled in a study. The stratified approach of only comparing events and patients within a trial compares only like with like and is not affected by differences in patient characteristics among the trials.
For each trial, the number of events observed in the treated group is contrasted with the number that would have been expected if treatment had no effect. If treatment were not beneficial, differences between the observed and the expected events (O-E) would differ only randomly from zero. A beneficial treatment effect with fewer events in the actively treated group would result in a negative O-E, whereas a harmful effect would result in a positive O-E. In a single trial, this tendency might be obscured by chance, but if several individual trials are combined, the grand total of all the 0-E values (GT) would approximate closer to the truth because such chance variations tend to average out and ultimately reinforce each other.
Determination of treatment effects from the GT assumes that information is available from all trials or an unbiased subsample. It Tables 1 and 2 .
Mortality data from a previously published and an up-to-date overview of all trials of streptokinase are also summarized in Table 3 
Description of Trials
Altogether, eight randomized trials of t-PA in acute MI7" 11-7 on a total of about 6,800 patients were identified through April 1990 (Table 1 ). About 1,750 patients have been studied in seven small trials1l-'7 in addition to ASSET,7 which randomized about 5,000 patients. The trials have many important similarities. They were all double blinded and placebo controlled. Treatment was started within 6 hours from onset of pain. Most of the small studies required ST-segment elevation on the admission electrocardiogram for inclusion, whereas two of the larger trials did not.7 '17 The dose administered was most often 100 mg of single-stranded t-PA (Alteplase, Genentech) given intravenously over 2-3 hours. In the studies of a double-stranded t-PA by Verstraete et at" (Genentech) and Armstrong et al'6 (Duteplase, Burroughs Wellcome), dosing was based on body weight. All trials used concomitant heparin intravenously. In all but one study,12 heparin (about 5,000 U) was administered as a bolus intravenously before the start of the study drug. In the study by Guerci et al,12 a bolus of 100 U/kg of heparin was given at the time of cardiac catheterization, 1-6 hours after the end of the study drug infusion. In three trials,1314'16 heparin infusion was continued immediately after the bolus for 48-96 hours; in four other trials,7"12'15"17 heparin infusion was started at the conclusion of the study drug or placebo infusion, whereas in one small trial," it was not stated whether further heparin was given.
Data on short-term mortality are available from all trials. Two other small randomized trials have been excluded from analysis.18"19 In both of these trials, interpretation of the results is difficult because patients with occluded infarct-related arteries, shown on an angiogram obtained at 45 minutes after intravenous therapy, were given intracoronary streptokinase or t-PA.
Ten randomized trials of APSAC on a total of approximately 2,000 patients were identified8'20-28 (Table 1 Figure 1) . Four of the trials were stopped early due to the publication of promising results in other studies.12 '14"16,17 In all trials except that by the National Heart Foundation of Australia Group,15 mortality was lower in the t-PA-treated group of patients. None of the treatment differences in the seven small trials was statistically significant. In the large ASSET trial,7 a significant 28% reduction in odds of death in the t-PA-treated group of patients was reported. When the results of the seven small trials were combined, a 33% reduction in odds of death in the t-PA-treated patients was found (p<0.05). Overall, in the eight trials, there were 230 (6.8%) deaths in the 3,390 patients allocated to active treatment compared with 315 (9.4%) deaths among 3,365 controls during the scheduled trial period of 1 month or less (the odds of death were decreased by 29%, with a 95% confidence interval of -41% to -16%). Data on long-term mortality have not yet been reported from any trial of t-PA.
Short-term mortality data are available also from all 10 APSAC trials (Table 3, Figure 1 ). The largest trial, AIMS,8 was stopped early due to clear evidence of a reduction in mortality in the group of patients treated with APSAC and the reduction in observed mortality in several independent trials of other thrombolytic therapy.12 There were 40 (6.4%) deaths among 624 patients treated with APSAC compared with 77 (12.1%) deaths among 634 controls, an apparent 50% reduction in odds. Five of the small trials reported a mortality in the group of patients treated with APSAC lower than among controls,9'21,23'24'28 and four trials reported an increase in mortality.22 '25-27 Overall, the odds reduction in the nine small trials was about 40% (p<0.05). The pooled data from all 10 trials indicate that there were 72 (6.1%) deaths among 1,177 patients treated with APSAC and 125 (11.0%) deaths among 1,138 controls (odds of death decreased by 46%, with 95% confidence interval of -60% to -28%). Long-term O-E, observed-expected; CI, confidence interval; t-PA, tissue-type plasminogen activator; APSAC, anisoylated plasminogen streptokinase activator complex.
was stopped early by the data monitoring committee after about half of the planned number of patients had been randomized. Because the decision to stop was made specifically at a time when there was strong evidence of benefit, the observed reduction could potentially overestimate the actual reduction to some extent simply by chance. The results of the overview of the independent small trials, however, support the large reduction in mortality observed in AIMS.8 Moreover, in AIMS8 both short-term and long-term data obtained subsequent to the decision to stop the trial were consistent with the earlier data. Although these data suggest the possibility of a large effect with APSAC, the 95% confidence limits of the data include a more modest effect (i.e., one third reduction in mortality). AIMS8 and other APSAC trials had inclusion criteria that were fairly restrictive. In contrast to other similar trials, for example, ISIS-22 and ASSET,7 only patients with ST-segment elevation at admission were included. Examination of a subset of patients in ISIS-22 (plus personal communication) with entry criteria similar to AIMS8 (presentation within 6 hours, with ST-segment elevation and 70 years of age or younger) also suggests a large benefit with streptokinase (43% reduction in the odds of death, 95% confidence limits of -53% to -32%). Moreover, the confidence limits of the estimates from the APSAC trials overlap considerably with those from the t-PA and streptokinase trials (Table 4) . Therefore, it is difficult presently to know from the available data whether APSAC is superior to other agents in reducing mortality. Direct compar- isons of these agents in large trials are essential in resolving which of the three available agents, if any, is more effective in reducing mortality.
Use of adjunctive therapy such as heparin and aspirin has probably not confounded the results of the trials in this overview. Heparin was used as concomitant therapy in both groups in all the trials, and aspirin was used in four small trials. Therefore, the use of these two agents would be expected to be similar and unbiased in the actively treated and control groups of patients and to not influence the analyses in this study. In light of the beneficial effects of aspirin shown in ISIS-2,2 the additive effect of the different thrombolytic agents against a background of aspirin therapy should be considered in future similar analyses.
Data comparing t-PA with streptokinase are available from the preliminary results of the GISSI-2 International Study on 20,749 patients (data presented at 39th Annual Scientific Session, American College of Cardiology, March 1990). All patients received aspirin. Each group was further randomized to receive 12,500 U heparin subcutaneously twice daily for a week, starting 12 hours after randomization, or was randomized to a control group. The in-hospital mortality rate was 8.9% among those randomized to receive t-PA compared with 8.5% among those randomized to streptokinase. Mortality was 8.5% in the group of patients receiving heparin compared with 8.9% among those patients allocated to control. Neither differences were statistically significant. The group of patients allocated to receive t-PA and heparin had a 9.2% mortality compared with 7.9% among those patients allocated to receive streptokinase and heparin (nominal, p<0.02). These data indicate that the lack of superiority of t-PA compared with streptokinase is unlikely to be due to differences in heparin use. Moreover, there appeared to be a greater risk of developing stroke in the group of patients receiving t-PA (1.35%) compared with those receiving streptokinase (0.95%,p<0.01).
Presently, it is reasonable to conclude that each of the three thrombolytic agents, streptokinase, t-PA, and APSAC, reduce mortality in acute MI and that the results are consistent and strengthened when all available trials are considered together. The available data suggest no major differences between t-PA and streptokinase. The data do not permit, however, a comparison regarding the relative efficacy of APSAC with the other two thrombolytic agents. The ISIS-3 trial comparing streptokinase, t-PA, and APSAC is expected to recruit over 50,000 patients.
The results of this trial are expected to be known in the spring of 1991. This trial will also provide information in a broader group of patients with suspected MI (e.g., electrocardiographic changes other than ST elevation, onset of symptoms >6 hours, and the elderly) compared with the GISSI-2 trial.
In recent times, overviews of randomized trials have gained acceptance as clinicians and clinical trial lists have realized that most treatments of common diseases produce only moderate reductions (e.g., 15%, 20%, or 25%) in major outcomes such as death. To detect such moderate differences reliably, large trials with several hundreds or even 1,000 end points are often required. In the absence of trials of such size, carefully conducted overviews are a method of evaluating the efficacy of treatment that is more reliable than reliance on the results of separate small trials. When large trials are available, overviews of all the data are still useful in confirming the results of the large trial, in obtaining a more precise estimate of effect size, and in conducting subgroup analysis. Particularly noteworthy in the two overviews presented in this paper is that the results of the overview of the small trials produced results very similar to the larger trials. Consistent with this, an overview of 25 small trials of intravenous urokinase or streptokinase3 published in 1985 predicted the results of GISSI1 and ISIS-2.2 These experiences are a practical demonstration of the validity of conducting overviews. It is worth emphasizing, however, that for an overview to be reliable, it should be based on a careful and exhaustive search for all trials conducted, a meticulous and unbiased extraction of data, and use of appropriate statistical methods. Conclusions should be cautious unless the results are fairly extreme (e.g.,p<0.001), and they should be based on a reasonable number of events. A detailed discussion of the advantages and limitations of overviews has been published previously.30
